Twin Lakes Capital Management LLC Sells 300 Shares of Jazz Pharmaceuticals PLC $JAZZ

Twin Lakes Capital Management LLC lowered its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 15.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,615 shares of the specialty pharmaceutical company’s stock after selling 300 shares during the period. Twin Lakes Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $201,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Jazz Pharmaceuticals by 4.7% in the first quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after acquiring an additional 74,501 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after acquiring an additional 391,660 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Jazz Pharmaceuticals by 8.3% in the fourth quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company’s stock worth $120,071,000 after acquiring an additional 75,000 shares in the last quarter. Finally, Perpetual Ltd boosted its holdings in Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock worth $118,212,000 after acquiring an additional 357,784 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $126.90 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $7.70 billion, a price-to-earnings ratio of -18.86, a PEG ratio of 7.97 and a beta of 0.24. The stock has a 50 day moving average of $117.88 and a 200 day moving average of $116.88. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on JAZZ shares. The Goldman Sachs Group increased their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a report on Friday, August 29th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Morgan Stanley increased their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.67.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.